Quick Answer
Mirum Pharmaceuticals, Inc. reported Net Income Loss of -$23.36 million for the year ending 2025.
- Mirum Pharmaceuticals, Inc. showed an increase of +73.4% in Net Income Loss from 2024 to 2025.
- This data is from Mirum Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: -$10.0 thousand | Q3 2018: -$67.0 thousand | Q1 2019: -$5.96 million | Q2 2019: -$13.56 million | Q3 2019: -$15.09 million | Q1 2020: -$21.31 million | Q2 2020: -$23.25 million | Q3 2020: -$21.51 million | Q1 2021: -$50.53 million | Q2 2021: -$43.89 million | Q3 2021: -$47.11 million | Q1 2022: -$36.61 million | Q2 2022: -$26.92 million | Q3 2022: -$35.71 million | Q1 2023: -$30.13 million | Q2 2023: -$74.04 million | Q3 2023: -$23.59 million | Q1 2024: -$25.28 million | Q2 2024: -$24.64 million | Q3 2024: -$14.24 million | Q1 2025: -$14.68 million | Q2 2025: -$5.86 million | Q3 2025: $2.91 million.
- Over the full 7 years of available data (2019 to 2025), Mirum Pharmaceuticals, Inc.'s Net Income Loss has grown by 55.5%.
- Historical annual values: Fiscal year 2025: -$23.36 million | Fiscal year 2024: -$87.94 million | Fiscal year 2023: -$163.42 million | Fiscal year 2022: -$135.67 million | Fiscal year 2021: -$83.99 million | Fiscal year 2020: -$103.27 million | Fiscal year 2019: -$52.55 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: